Cancer Virology Program

摘要：癌症病毒学(CV) 大约15%的人类癌症是由病毒引起的。在取得重大进展的同时， 在过去的几十年里，还没有针对多种癌症病毒的疫苗或特定的靶向疗法。 以及与之相关的恶性肿瘤。癌症病毒学(CV)计划的使命，这是密切一致的 与希尔曼癌症中心(HCC)合作的目标是通过获得新的 关于病毒感染的知识。CV成员将通过识别新的靶向癌症途径来实现这一目标 通过癌症病毒(目标1)；确定病毒癌症的新治疗靶点/制剂并开发新的 抗癌病毒疗法(目标2)；确定病毒癌症的新生物标记物(目标3)；以及 发现新的致癌病毒(目标4)。为了促进这些具体目标的实现，简历有 制定了切实的目标，即建立一个富有成效、高度合作的调查小组 致力于这些目标，在癌症病毒学领域为肝癌提供独特的智力资源，并建立 与多代科学家一起研究癌症病毒的特殊研究计划。作为一种 本课程的优势在于得天独厚的学术环境和丰富的学术资源。 肝细胞癌。CV通过为使用癌症的基础癌症研究提供肥沃的土壤来实现这些目标 病毒和病毒癌症作为模型系统，积极招募癌症病毒学研究人员，支持 内部和外部互动和协作，用于计划研讨会，用于内部和外部 研讨会和务虚会以及癌症病毒学试点项目研究，刺激流域研究 用于指导初级调查员和受训人员。在高守江的领导下， 博士，简历有27名成员，代表匹兹堡大学的9个系和3个学院。心电 成员开展癌症研究，每年直接资助810万美元，其中290万美元 是NCI的资金，500万美元是其他同行审查，20万美元是非同行审查。2015-2019年8月，简历 成员发表了428份与癌症有关的出版物，占方案内的9%，方案间的19% 方案，以及65%的机构间合作。CV是国际公认的领先的 新的人类癌症病毒的发现和表征。高效率的研究工作 当前供资周期中的计划成员反映了个人简历在实现这些目标方面的成功，这些目标将是 在下一个供资周期实现和扩大。

Abstract: Cancer Virology (CV) Viruses are the cause of approximately 15% of human cancers. While significant advancements have been made in the last few decades, there is no vaccine or specific targeted therapy for numerous cancer viruses and their associated malignancies. The mission of the Cancer Virology (CV) Program, which is closely aligned with that of Hillman Cancer Center (HCC), is to prevent and cure viral and nonviral cancer by acquiring new knowledge of viral infection. CV members will achieve this goal by identifying new cancer pathways targeted by cancer viruses (Aim 1); identifying novel therapeutic targets/agents for viral cancer and developing new anticancer virus-based therapeutics (Aim 2); identifying novel biomarkers for viral cancers (Aim 3); and discovering new cancer-causing viruses (Aim 4). To facilitate the execution of these specific aims, CV has developed tangible goals, which are to establish a productive, highly collaborative group of investigators devoted to these aims, provide unique intellectual resources to HCC in the area of cancer virology, and build an exceptional research program with multiple generations of scientists studying cancer viruses. As an integral program of HCC, CV takes advantage of the exceptional academic environment and rich resources of HCC. CV achieves these goals by providing fertile ground for fundamental cancer research using cancer viruses and viral cancers as model systems, active recruitment of investigators in cancer virology, support for internal and external interactions and collaborations, for program symposiums, for internal and external seminars and retreats and for pilot project research in cancer virology, stimulation of research in the catchment area, and for mentoring of junior investigators and trainees. Under the leadership of Shou-Jiang (SJ) Gao, PhD, CV has 27 members representing 9 departments and 3 schools within the University of Pittsburgh. CV members conduct cancer-focused research supported by $8.1M in total annual direct funding of which $2.9M is NCI funding, $5.0M is other peer-reviewed and $0.2M is non-peer-reviewed. From 2015-August 2019, CV members published 428 cancer-related publications representing 9% intra-programmatic, 19% inter- programmatic, and 65% inter-institutional collaborations. CV is internationally recognized as a leading hub for the discovery and characterization of new human cancer viruses. The high research productivity of the program members in the current funding cycle reflects the success of CV in meeting these goals, which will be realized and augmented in the next funding cycle.